undamentalytics Newsletter

Bristol Myers Squibb balance sheet

At the end of fiscal 2025, Bristol Myers Squibb had total assets of $90.04bn, total liabilities of $71.53bn and shareholders' equity of $18.47bn. It held $10.21bn in cash against $47.09bn of debt: net debt of $36.88bn.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Bristol Myers Squibb: balance sheet, annual
Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents7.75.05.81.73.65.62.44.25.46.912.314.514.09.111.510.310.29.6
Receivables1.92.02.31.71.72.12.93.84.34.66.57.28.08.28.99.09.69.2
Inventory1.41.21.41.71.51.61.21.21.21.24.32.12.12.32.72.62.72.7
Total current assets14.013.315.39.518.914.610.413.714.917.729.430.233.327.331.829.829.429.8
Goodwill5.25.25.67.67.17.06.96.96.96.522.520.520.521.121.221.721.821.7
Total assets31.031.133.035.938.633.731.733.733.635.0129.9118.5109.396.895.292.690.088.8
Accounts payable1.72.02.62.22.62.51.61.72.21.92.42.72.93.03.33.63.64.6
Deferred revenue (current)0.2—————————————————
Total current liabilities6.36.77.88.312.48.58.08.89.610.718.319.121.921.922.323.823.418.8
Short-term debt0.20.10.10.80.40.60.11.01.01.73.32.34.94.33.12.02.31.0
Long-term debt6.15.35.46.68.07.26.65.77.05.643.448.339.635.136.747.642.941.8
Total debt6.45.45.58.18.47.86.76.78.08.649.552.749.343.242.651.547.143.6
Total liabilities16.215.417.122.323.418.817.317.421.720.978.280.673.365.765.776.271.565.4
Shareholders' equity14.815.716.013.615.214.914.316.211.714.051.637.835.931.129.416.318.523.4
Net debt (negative = net cash)−1.30.4−0.36.44.82.34.32.52.51.737.238.135.334.131.241.136.934.1

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BMY vs NVOBMY vs GSKAZN vs BMYBMY vs PFE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Bristol Myers Squibb's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bristol Myers Squibb.